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The effects of 5-fluorouracil and interferon-a on early healing of 
experimental intestinal anastomoses
JWD de Waard*, T Wobbes, BM de Man, CJ van der Linden and T Hendriks
Summary The continuing search for effective adjuvant therapy after resection of intestinal malignancies has
prompted a growing interest in both immediate post-operative regional chemotherapy and the combination of 
5-fluorouracil (5-FU) and interferon-a as drugs of choice. We have compared the effects of both compounds, 
alone and together, on early healing of intestinal anastomoses. Four groups (n**26 each) of rats underwent 
resection and anastomosis of both ileum and colon: a control group and three groups receiving intraperitoneal 
5-FU, interferon-a or both on the day of surgery and the next 2 days. Animals were killed 3 or 7 days (« *  10 
each) after operation in order to measure anastomotic strength and hydroxyproline content. The remaining six 
animals in each group were used to study anastomotic collagen synthetic capacity at day 3. Three days after
operation, ileal anastomotic bursting pressure was lowered by 37% in the 5-FU/interferon-a
( P *0.0104). At day 7, anastomotic breaking strength was reduced significantly in ileum (P~~0.0221) and 
colon ( P -  0.0054) of the 5-FU/interferon-a group and in colon of the interferon-a group (P *  0.0221). Collagen 
synthetic capacity was strongly suppressed by 5-FU but not by interferon-a. However, no differences in 
anastomotic hydroxyproline content were observed between groups at both days 3 and 7. Thus, post-operative 
use of interferon-a, in particular in combination with 5-FU, may be detrimental to anastomotic repair in the
intestine.
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Despite the high resectability rate and general improvement 
in surgical therapy, nearly half of all patients with colorectal 
cancer will eventually die from recurrent disease. Candidates
for post-operative adjuvant therapy are patients at risk for
disease relapse, as judged by clinical evaluation, surgical
examination and pathological examination of resection 
specimens. In general, safe and effective adjuvant therapy 
would be highly desirable in patients with Dukes’ stage B2
and C colon carcinoma, which constitute 60 -70% o f the 
population presenting with colorectal cancer.
Over the last three decades numerous studies have shown 
little or no survival benefit, although small but significant
improvement, from chemotherapy
using 5-fluorouracil (5-FU) as the primary agent (Kemeny 
el al., 1993; Moertel, 1994). Presently, preclinical and clinical 
protocols aim to increase the activity of 5-FU-based adjuvant 
therapy. The optimal manner in which 5-FU should
administered still remains to be determined. There appear to
reasons to start treatment immediately after 
operation (Harris and Mastrangelo, 1991) and to administer 
drugs intraperitoneally (Cunliffe and Sugarbaker,
o f
in
immediate post-operative regional chemotherapy (Pàhlman,
trials shows 
that include
•t has also been directed at enhancing the 
activity of 5-FU by drugs such as leucovorin and levamisole. 
Recently, the potential o f the interferons has been recognised 
in this respect. Interferons are a family of multifunctional
proteins and components of the host defence against viral 
and parasitic infections and malignancy (Sen and Lengyel, 
1992). In vitro studies have demonstrated that each type of 
interferon may interact with fluoropyrimidines in a synergistic 
manner to produce cytotoxicity in a variety o f human cancer 
cell lines (see Grem et al., 1995). In phase II trials in patients
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with advanced colorectal carcinoma the combination of 
interferon-a, plus or minus leucovorin, with 5-FU appears 
to possess higher activity than 5-FU alone (Grem et al., 1991; 
Pazdur, 1991; Wadler et al., 1991). This increased activity is 
the result of biochemical modulation of 5-FU metabolism, 
with both enhancement of the inhibition of 
synthase and alteration of the pharmacokinetics o f 5-FU
Accepting the hypothesis that immediate post-operative 
administration of interferon-a, together with 5-FU,
benefit patients after resection o f colorectal carcinoma, it 
becomes essential to investigate the potential effects o f these
drugs on early anastomotic healing in the intestine. Loss of
wound strength increases the risk for anastomotic dehiscence,
which is a most serious surgical complication with 
concomitant high mortality and morbidity. Previous experi­
ments in our laboratory have shown that 
intraperitoneal combination chemotherapy containing 5-FU
reduces early anastomotic strength 
Zuidewijn et al., 1991). In addition, daily intraperitoneal 5- 
FU alone from the day of operation onwards strongly 
inhibits anastomotic repair in the rat intestine (Graf et al
1992; de Waard et a!., 1995a). If administration o f 5-FU
remains limited to the day of operation and the first two 
post-operative days anastomotic strength is not significantly 
affected (de Waard et al., 1993). In a recent experiment we
5-FU plus levamisole orhave examined 
leucovorin on anastomotic healing (de Waard et al., 1995h). 
Here, we describe our experiments into the effects of a 3 day 
post-operative course of interferon-a and interferon-a plus 5-
FU on early healing of intestinal anastomoses in the rat.
Materials and methods
Altogether, 104 male outbred Wistar/Cpb:WU rats, weighing 
between 200 and 300 g, were used. They were housed with 
two animals per cage and had free access to water and
standard laboratory chow AM II, Hope farms,
Woerden, The Netherlands).
For the measurement of anastomotic and
hydroxyproline content, 80 animals were randomly divided
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into four groups of 20 animals each: a control group, a 5-FU was counted. Subsequently, in order to determine proline 
group, an interferon group and a group receiving 5-FU plus incorporation into collagen, excess purified collagenase was
W ithin added. The radioactivity in the supernatant represents CDP, as
days after operation. Collagen synthesis was measured in a measure o f the amount o f collagen synthesised. Subtraction 
similar groups of animals (11 =  6 each in each group). These o f the radioactivity in the CDP fraction from that in total 
rats were killed 3 days after operation. The study was protein yields the incorporation into non-collagenous protein 
approved by the Animal Ethics Review Committee of the (NCP). The relative collagen synthesis (RCS) was calculated
with the formula (Peterkofsky et al., 1981) that takes into 
account the enrichment o f proline in collagen compared with
Faculty of Medicine, University o f Nijmegen.
other proteins:
Relative collagen synthesis (%)
CDP
(NCP X 5.4) +  CDP
X 100
Drug administration
5-FU (Abie, Netanya, Israel) was given intraperitoneally in a 
dose o f 20 mg kg ' 1 body weight (concentration: 1 mg ml“ 1 
saline). This is the same dose we used before (de Waard et al.,
1993, 1995a,Z>) and represents the highest dose which, in 
combination with surgery, did not result in a significant Incorporation is expressed on the basis o f sample wet weight,
mortality. Recombinant rat interferon-a (van der Meide et 
al,  1986; specific activity 6 x 10A U mg"1 protein) was 
administered intraperitoneally in a dose of 2 x l 0 4 U k g " 1 
body weight (concentration: 2 x  103 U m l"1 saline). The drugs 
were given once a day, on the day of operation and the next 
2 days. The animals in the control groups received 
intraperitoneal saline daily.
Operative procedure
After an intraperitoneal injection of sodium pentobarbital, a 
midline incision was made and 1 cm of both small and large 
bowel was resected, at 15 cm proximal to the ileocaecal 
junction, and 3 cm proximal to the rectal peritoneal reflection 
respectively. Continuity was restored microsurgically by the 
construction of an inverted one-layer seromuscular end-to- 
end anastomosis with eight interrupted sutures of 8 x 0  
monofilament material (Ethicon, Sommerville, USA). The 
abdomen was closed in two layers with a continuous 3 x 0  
silk suture for the fascia and staples for the skin.
Analy t icaI procedures
The rats were killed by an intraperitoneal overdose of sodium
pentobarbital. After opening the abdominal wound and 
identifying the anastomoses, the adhesions were cut as far 
as possible without injuring the intestine. An intestinal 
segment with the anastomosis in the middle was removed, 
with the sutures left in place. This segment was attached to 
an infusion pump filled with methylene blue-stained saline. 
The pressure was raised with an infusion rate o f 4 ml m i n 1 
and recorded graphically. Both the bursting pressure, i.e. the 
maximum pressure recorded immediately before sudden loss 
of pressure, and the site of rupture were noted. Thereafter, 
the segment was placed in a tensiometer, and the breaking 
strength was recorded. Thus, both the bursting pressure and 
breaking strength were measured in the same anastomotic 
segment. The validity of this procedure has been confirmed in 
a pilot experiment. Anastomotic breaking strength was 
compared in two groups of rats, either measured directly or 
after the procedure used for measuring the bursting pressure, 
and found to be similar in both groups (de Waard et al., 
19956). The anastomotic segment was then cleaned from the 
surrounding tissue and a 5 mm segment with the suture line 
in the middle was collected. The samples were frozen 
immediately and stored in liquid nitrogen until processing. 
After weighing, the samples were pulverised and lyophilised 
and the hydroxyproline content was measured as described 
before (Hesp et a l ,  1984).
Collagen synthesis was analysed as the ex vivo collagen 
synthetic capacity in intestinal explants by measuring the 
incorporation of proline into collagenase-digestible protein 
(CDP), according to a procedure validated before for rat 
intestinal tissue (Martens et al., 1992). Briefly, tissue explants of 
1 -  2 111m2, freshly collected from control segments removed at 
operation and from anastomotic tissue removed 3 days after 
operation, were incubated in medium containing [3H]proline 
for 3 h and the radioactivity incorporated into total protein
D N A  (Burton, 1956) content or protein (Smith et a l ,  1985) 
content.
Statistical analysis
To correct for the fact that multiple comparisons were made, 
pairwise comparisons of groups were performed (with a two- 
tailed M ann-W hitney test) using a level o f significance of 
a 1 = 2 ajk, where k  is the number of pairwise comparisons. 
For instance, differences between the three experimental 
groups and the control group (Figures 2 - 4 )  were considered 
significant (a = 0.05) at P < a 1, where a 1 = 2 x 0 .0 5 /3  = 0.033.
Results
N o animals died prematurely during the experimental protocol. 
Up to 24 h after operation, all rats lost approximately 8% of 
their body weight. Thereafter, animals regained weight, 
although clear differences were observed between groups 
(Figure 1). Weight gain in the 5-FU group was significantly 
slower than in the control group. Administration of
120
JZ
CD
'3
>TJo_Q
110
100
CO
0
03
90
ca>o
L _
CDCL. /  / /
10
0
0 1 2 3 4 5 6 7
Days after operation
1 Course of body weight. Data represent mean values 
10) and, for the control group only, the s.d. (O ), control
group; (# ), interferon-a group; (A ), 5-FU group; (A ), 5-FU/ 
interferon-a group. Significant differences (P c 0.033, see Materi­
als and methods) between groups are denoted by # (interferon-a 
vs control group), * (5-FU vs control group) and $ (5-FU vs 
5-FU/interferon-a group).
interferon-a appeared to increase the rate of weight gain over 
the first post-operative days: mean body weight was 
significantly higher in the interferon-a group than in the 
control group from day 3 onwards, and in the 5-FU/interferon- 
a group than in the 5-FU group from day 5 onwards.
Anastomotic strength may be assessed both from the 
bursting pressure, which represents its resistance to 
intraluminal pressure, and from the breaking strength, which 
reflects its ability to withstand longitudinal forces.
Figure 2 depicts the outcome of all measurements of 
anastomotic bursting pressure performed at 3 days after 
operation. At this time the bursting site was always within 
the anastomotic area. In altogether six (out of 80) 
anastomoses the bursting pressure could not be measured 
because o f technical problems. Neither 5-FU nor interferon-a 
administration led to a significant change in bursting 
pressure. However, the mean bursting pressure o f ileal 
anastomoses in the 5-FU/interferon-a group (44 ± 7  minHg) 
was significantly (P = 0.0104) lower than that in the control 
group (70 ± 2 0  mmHg). In addition, it was also significantly 
reduced with respect to the 5-FU group ( P -  0.0037) and the 
interferon-a group (P — 0.0062). In colon, these differences 
did not reach statistical significance. At 7 days after 
operation the bursting site was always outside the suture 
line and therefore the bursting pressures measured (data not 
shown) did not reflect actual wound strength.
When measuring the breaking strength (Figure 3) the 
breaking site was invariably located within the wound area. 
At 3 days after operation no differences were found between 
groups, but after 7 days the breaking strength o f  both ileal 
and colonic anastomoses was significantly lower in the 5-FU/ 
interferon-a group than in the control group. Also, 
anastomotic breaking strength in the colon was reduced in 
the interferon-a group.
The hydroxyproline content in 5 mm segments containing 
the anastomosis was quantitated as a measure of wound 
collagen levels (Figure 4). No differences between the control 
group and the experimental groups were observed. The 
hydroxyproline content increased similarly from 3 to 7 days 
after operation independent of medication. Likewise, no
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differences were found for hydroxyproline concentrations.
Mean hydroxyproline concentrations were 7.0 ±1.3
i
and
9.6 ±  1.8 pig m g~‘ dry weight in 3- and 7-day-old ileal 
anastomoses respectively; corresponding values in colonic
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anastomoses were 9 .7±0.7  and 13.8+1.9 ug mg i dry with wound healing. Indeed, 5-FU administered daily from
weight. Similar values were measured in the experimental the day o f operation onwards until sacrifice after 7 days
groups (data not shown).
The collagen synthetic capacity, measured ex vivo in tissue
in control segments removed at
the
explants, was assé
operation and in 3-day-old anastomotic tissue from 
same rats. Table I shows that in the control group collagen 
synthetic capacity, expressed on the basis of DNA, wet 
weight or protein, was strongly increased in wound tissue. 
This increase was significantly (?  = 0.0313) higher in ileum 
than in colon. The fact that the percentage relative collagen 
synthesis was also elevated indicates that collagen synthesis 
was stimulated to a larger extent than the synthesis of non- 
collagenous proteins. Figure 5 depicts the anastomotic 
collagen (and non-collagenous protein) synthetic capacity, 
calculated on the basis of DNA content, for the various 
groups. Treatment with 5-FU significantly reduced collagen 
synthetic capacity without affecting the production of non- 
collagenous protein. In contrast, treatment with interferon-a 
did not appear to affect these processes to any substantial 
degree since no significant differences were seen between the 
interferon-a group and the control group or between the 5- 
FU/interferon-a group and the 5-FU group. Similar results 
were obtained if the collagen synthetic capacity was expressed 
on the basis of wet weight or protein content (data not 
shown).
Discussion
The continuing search for effective adjuvant therapy after 
resection of colorectal carcinoma has resulted in a growing 
interest in the efficacy of both immediate post-operative 
regional chemotherapy (see Pâhlman, 1995) and the 
combination of 5-FU with interferon-a as the cytostatic 
drugs of choice (see Grem et al., 1995). The present results
indicate caution should be exerted in the use of
interferon-a as an adjunct to 5-FU therapy in the early 
post-operative period since such treatment might constitute a 
threat to undisturbed anastomotic healing. The combination 
of interferon-a and 5-FU, administered intraperitoneally on 
the day of operation and the first two post-operative days, 
reduces the development of anastomotic strength during the
its construction. Administration of 5-FUfirst week
alone has no significant deleterious effect on wound strength, 
but interferon-a in itself significantly lowers strength below 
control values in 7-day-old colonic anastomoses.
The wound healing process is characterised by massive cell 
migration and proliferation. Cytostatic drugs are by nature 
anti-proliferative and may therefore be expected to interfere
Table I Increase in anastomotic collagen synthetic capacity 3 days
after operation
Control
segment Anastomosis Ratio
Ileum
D.p.m. /tg DNA 41 ±6 194 ± 30 4.9 ¿1.2
D.p.m. mg 1 
D.p.m. mg“1
wet weight 85 ±24 595 ± 72 7.6 ±2.2
protein 2578 ±654 14786 ±1953 6.0 ± 1.4
RCS (% ) 0.47 ±0.08 1.02±0.18 2.2 ±0.5
Colon
D.p.m. /¿g 
D.p.m. mg 
D.p.m. mg'1
DNA 86 ± 18 221 ±62 2.6 à 0.9
wet weight 305 ±45 773 ±150 2.6 ±0.7
protein 7317 ±1019 17454 ±3214 2.4 ±0.4
RCS ( % ) 1.12 ±0.12 1.72 ±0.32 1.5 ± 0.2
Explants from control segments, collected at operation, and 
anastomotic tissue, collected 3 days after operation, were incubated 
for 3 h with 4.5 ¡ id  of [•’HJproline, Collagen synthesis is expressed as 
radioactivity in collagenase-digestible protein and as percentage 
relative collagen synthesis (RCS). Data represent average values 
(+ s.d.) from six animals.
severely impairs anastomotic healing in the rat intestine (Graf 
et al., 1992; de Waard et a l ,  1995b). In earlier experiments, 
we tried to mitigate this negative effect by concomitant 
administration o f either interleukin 2 or granulocyte-  
macrophage colony-stimulating factor, but 5-FU impaired 
repair was not essentially altered by either cytokine. On the 
other hand, retinol significantly promoted 5-FU suppressed 
anastomotic healing (de Waard et al., 1995a). Also, we 
reported before that the negative effect is limited if 5-FU is 
given only three times (de Waard et al., 1993, 1995a). Since 
we expected any additional effect of interferon-a to be 
observed more easily under the latter conditions, we limited 
drug administration to the first 3 days.
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Figure 5 Anastomotic collagen synthetic capacity. Bars represent 
mean values (/? = 6)~Hs.d. of ex viva synthesis of collagen (a, 
expressed as radioactivity in collagenase-digestible protein; c, 
expressed as percentage relative collagen synthesis, RCS) and 
other proteins (b, expressed as radioactivity in non-collagenous 
protein), 1, control group; 2, 5-FU group; 3, interferon-a group; 
4, 5-FU/interferon-a group. Differences between groups are 
considered significant at PcO.017 (see Materials and methods) 
and nearly significant (symbols in brackets) at P < 0.033, *, 
significant vs control group; $, significant vs 5-FU group; #, 
significant v.v interferon-a group.
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So far, little is clear about the effects o f interferons on 
wound healing. Interferon-}’, delivered intraperitoneally 
through an osmotic pump (Granstein et al., 1989) or injected 
subcutaneously (Miles et al., 1994), has been found to delay 
skin repair in mice. In the latter study, wound disruption 
strength was reduced significantly at a dose o f 7 x 104 U k g-1 
body weight and higher. Two experiments, with opposite 
results, have been reported on the effects o f interferon-a//} on
experiments with fibroblasts (Jimenez et al., 1984; Duncan 
and Berman, 1985), which are the primary producers of 
extracellular matrix in the healing wound. Indeed, histologi­
cal examination of interferon-y-treated wounds indicates 
reduced accumulation of collagen (Granstein et al., 1989; 
Miles et al., 1994). However, our data show that treatment 
with interferon-a alone does not lead to lowering of either ex 
vivo collagen synthetic capacity in anastomotic explants or
cutaneous healing in rodents. Intramuscular injection of hydroxyproline accumulation in anastomotic segments. Such
interferon-a//? or intraperitoneal administration of polyino- 
sinic-polycytidylic acid, a potent inducer o f interferon, 
seemingly enhances repair (Bhartiya et al., 1992), while local 
subcutaneous injection of interferon-a//? beneath the wound 
actually inhibits repair (Stout et al., 1993). In these studies, 
evaluation of repair was solely on the basis o f macroscopic or 
histological parameters; functional parameters, like wound 
strength, were not reported.
The present study is the first effort to investigate the effect 
of purified interferon-a on wound strength. Rat recombinant 
interferon-a was given in a daily dose o f 2 x 104 U kg~1 body 
weight. This dose is more than sufficient to protect rats 
against a lethal pseudorabies virus (PH van der Meide, 
personal communication), but is substantially lower than the 
doses of interferon employed in the studies mentioned above. 
Still, daily doses o f this relatively low dose o f interferon-a, 
administered on the first three post-operative days, signifi­
cantly reduce anastomotic breaking strength in the colon 7 
days after operation. The results of treatment with the 
combination o f 5-FU and interferon-a are probably of more 
immediate interest in terms of potential treatment of patients 
with colorectal cancer. It seems clear that addition of 
interferon-a to a regimen of 5-FU, which in itself does not 
affect anastomotic strength, may lead to a significant and 
substantial reduction in anastomotic strength during the first 
week of healing. In this period, where clinically most leakages 
occur, the strength of the anastomosed segment is relatively 
low as compared with the strength of the uninjured intestine; 
any further reduction constitutes a threat to anastomotic 
integrity and increases the chances for anastomotic dehis­
cence. Thus, these data should be treated as a warning that 
clinical application of 5-FU plus interferon-a immediately 
after anastomotic construction, although possibly beneficial 
with respect to adjuvant effectivity, may result in undesirable 
(side-) effects with respect to wound repair.
It remains to be determined how exactly interferon-a 
interferes with the healing sequence. The strength of both the
and the sutured bowel wall depends to a large
extent on collagen and anastomotic construction leads very 
quickly to an increased collagen synthetic capacity within the 
wound area (Martens and Hendriks, 1991). Interferons are 
known to be able to inhibit collagen synthesis (Granstein et 
al., 1990). This suppressive effect is well established by in vitro
an effect is indeed observed after 5-FU treatment, but again 
addition of interferon-a does not lead to further reduction. 
This lack of effect of interferon-a may be explained by the 
relatively low doses we used. Alternatively, it could be that 
interferon-a has less effect on matrix production than the 
other interferons. Experiments with isolated cells show this to 
be true for fibroblast collagen synthesis, both on the protein 
(Jimenez et al., 1984; Duncan and Berman, 1985) and the 
mRNA level (Duncan et al., 1995).
Anastomotic strength will also be affected by degradation 
of the existing matrix anchoring the sutures. The methodol­
ogy used to measure the hydroxyproline content in 
anastomotic segments, which necessarily contain uninjured 
tissue next to the actual wound area, does not allow the 
detection of very localised loss o f collagen. It may be that 
interferon-a increases collagenase expression (Duncan and 
Berman, 1989; Hujanen et al., 1994), although macrophage 
metalloproteinase production appears to be inhibited by 
interferon-)) (Wahl and Corcoran, 1993).
Finally, one could speculate that interferon-a interferes 
with healing by the inhibition of proliferation, either directly 
or by biochemical modulation of 5-FU metabolism. 
Interferons are growth inhibitors for a variety o f normal 
and transformed cell lines (see Mallat et al., 1995). The 
impairment o f cutaneous healing by interferon-a/^ is thought 
to be caused primarily by inhibition of proliferation of all cell 
types involved in wound repair (Stout et al., 1993). More 
specifically, interferon-a is known to inhibit endothelial cell
proliferation and angiogenesis (Folkman,
processes inherent to successful repair.
Whatever the mechanism(s) responsible, our data clearly 
indicate that administration of interferon-a in the periopera­
tive period may be detrimental to anastomotic repair and 
that its use in immediate post-operative adjuvant therapy, as 
a means to enhance 5-FU activity, should be approached 
with caution.
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